Welcome to the TLDR Biotech newsletter!

Our aim is to be your one-stop source for biotech and pharma updates - all with one daily email.

We’ll likely tweak the exact format and delivery over the next few weeks as we get our feet under us.

So if you have any feedback on what you like (or don’t), we’d love to hear from you!

MINOR HOUSEKEEPING
How these updates are formatted

The newsletter is split into three main sections:

• THE GOOD - good news (eg. fundraises, product approvals)

• THE BAD - negative news (eg. clinical trial failures, layoffs)

• THE UGLY - negative but atypical news (lawsuits, product recalls, scandals)

Within each of the three above parts, there are additional sections for easier navigation:

• Eg. There will be multiple “The Good” sections covering things like Fundraises, Approvals, Partnerships etc.

• There will be also additional tags within these sections (Eg. fundraises may mention Stage, product approvals may mention drug name and disease area.)

See something you want to get into further? Click the Read More (goes out to either a news article or a press release).

THE GOOD
Approvals

Outset Medical comeback on FDA approval
Medical device, dialysis - Read more

THE GOOD
Clinical Trials

Verve Therapeutics doses first participate with back-up gene-editing therapy
Gene therapy, gene editing, heart disease - Read more

Regeneron reports initial positive deafness gene therapy results
Gene therapy, genetic deafness - Read more

Teva and MedinCell score Phase 3 schizophrenia win
Small molecule, controlled release, schizophrenia - Read more

Compass Pathways reports positive mid-Phase 3 data
Small molecule, psilocybin, psychedelics, PTSD - Read more

Calliditas misses on tumor shrinkage, but wins on survivability
Small molecule, solid cancers - Read more 

After CRISPR-embryo debacle, gene-editing trials are starting again in China
Gene-editing, CRISPR - Read more

THE GOOD
Company Launch

Prologue Medicines launches with $50M from Flagship Pioneering
Viral protein therapeutics, cancer, immune disorders - Read more

THE GOOD
Earnings & Finances

Sandoz makes bank on Humira biosimilar
Overall 6% 2024Q1 growth rate
mAb, biosimilar, Humira - Read more

Vertex Pharmaceuticals smashes earnings expectations
Net income: $1.10B (up 57% from 2023Q1)
Gene therapy, gene-editing, cystic fibrosis - Read more

THE GOOD
Expansions

Sharp Services plans PA site expansion
Clinical supply, secondary packaging, sterile injectables - Read more

Beigene plans fourth facility, $74M budget
Cancer, manufacturing - Read more

THE GOOD
Fundraises

MassBio partners to launch South Carolina-based life sciences accelerator
Accelerator, seed-stage - Read more

Nanochon raises $4M seed round
Orthopedics, medical device - Read more

Think Bioscience announces $6M seed round expansion
Small molecule, undruggable - Read more

Cache raises seed funding, amount undisclosed
Biological sample storage, data storage - Read more

Ciba Health raises $10M Series A
Digital health - Read more

Backpack Healthcare raises $14M Series A
Digital health, mental health, pediatrics - Read more

Averto Medical raises $30M Series A
Medical device, gastrointestinal, surgery - Read more

Zenas BioPharma raises $200M Series C
mAb, autoimmune - Read more

Memo Therapeutics raises $22M (CHF 20 million) Series C extension
Antibody, kidney transplant, infectious disease - Read more

NSG BioLabs raises $14.5M financing round
Laboratory space, biotech office space - Read more

THE GOOD
Mergers & Acquisitions, Business Development

Arbor Biotechnologies buys Serendipity Bioscience
Deal terms not disclosed
CRISPR, gene editing - Read more 

THE GOOD
Opinions

Your body, the bioreactor? Or, The Future of Regenerative Medicine - Read more

AstraZeneca US oncology head has high hopes for AI - Read more

THE GOOD
Partnerships

Nucleus RadioPharma and ARTBIO manufacturing partnership
Radiopharmaceuticals, prostate cancer - Read more

CytomX Therapeutics and Merck (MSD) sign research collab
Protein, antibody (keytruda), solid cancer - Read more

ExcellGene, Cytovance manufacturing partnership
Large molecule biologics, manufacturing - Read more

BioVersys, GSK expand tuberculosis clinical research pact
Small molecule, tuberculosis - Read more

THE GOOD
Politics & Policy

White House release “research of concern” policy - Read more

THE GOOD
Product Launch

Madrigal builds MASH-treatment launch hype
Small molecule, MASH, liver fibrosis - Read more

Google Deepmind, Isormorphic Labs debut AlphaFold 3
AI, protein modelling, protein simulations - Read more

Biosense Webster’s new heart-mapping tool
Cardiac modelling - Read more

THE GOOD
Regulatory

Accelerated approvals necessary according to Peter Marks - Read more

THE GOOD
Research

Personalized, mRNA cancer vaccines hold promise for glioblastoma - for you and your dog
mRNA, cancer vaccine, glioblastoma - Read more

THE GOOD
Strategic Plans

Krystal Biotech shows-off gene therapy spoils, plans international launches
Gene therapy, dystrophic epidermolysis bullosa - Read more

THE BAD
Company Shutdown

Walking Fish Therapeutics shutters after lead investor ditches
Cell therapy, Fabry disease - Read more

THE BAD
Earnings & Finances

Apellis stock slides on increased competition, despite strong revenue
Synthetic peptide, geographic atrophy - Read more

LabCentral struggles as capital and financing stays expense
Lab space, research space - Read more

THE BAD
Layoffs

With J&J pact out the window, Kenvue plans layoffs
Consumer health - Read more

Marinus Pharmaceuticals layoffs, 20% of current staff
Small molecule, refractory status epilepticus - Read more

For Teva Pharmaceuticals, “pivot to growth” means site shutdowns
Manufacturing, generics - Read more

THE BAD
Partnerships

Pharming Group, Orchard Therapeutics cut-off gene therapy collab
Gene therapy, hereditary angioedema - Read more

THE UGLY
Clinical Trials

Pfizer reports death in DMD gene therapy trial
Gene therapy, Duchenne muscular dystropy - Read more

THE UGLY
Lawsuits

Pfizer moves to settle 10k Zantac cancer-risk lawsuits
Small molecule, cancer, heartburn - Read more

THE UGLY
Politics & Policy

FDA gets looped in on USA’s China-biosecurity crackdown - Read more
Geopolitics, USA-China relations

THE UGLY
Regulatory

CBER & FDA head honchos aren’t pleased about gene therapy drug pricing
Gene therapy, drug pricing - Read more

THE UGLY
Withdrawals

AstraZeneca withdraws COVID-19 vaccine - Read more

You’re all caught up on the latest Pharma & Biotech News!

We want to hear from you! 📣 

Have comments/questions/complaints about this newsletter?
Send us an email - we want your brutally honest feedback. 📝

And if you like this newsletter and think a friend or colleague would benefit, please share this with them! ♻️

Want to sponsor this newsletter and reach an audience of biotech and pharma professionals? Reach us here. 👍

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here. 🔍